Nicotinamide riboside (NR) and metabolic

What 2 graded rows on nicotinamide riboside (nr) agree on for metabolic, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Nicotinamide riboside (NR) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Nicotinamide riboside (NR) page, with its PubMed record.

Supplement

Nicotinamide riboside (NR) Choose another

2 rows · 53 people

Split. 1 row found an improvement and 1 found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

Trial sizeHow longWho was studiedWhen publishedGrade

The best-graded row, grade C, is a randomized trial of 40 people (2018) and found no difference.

The row that found no difference was larger: 40 people, against 13 people for the row that found an improvement.

The row that found no difference ran longer (3 months) than the row that found an improvement (6 weeks).

Only the row that found an improvement names women in its population.

The row that found an improvement is newer (2020) than the row that found no difference (2018).

The best grade is C among the row that found no difference, and D among the row that found an improvement.

1 improved · 1 no difference

Grade DFat-free mass and sleeping metabolic rate · Improved
Crossover RCT · n 13 · 2020 · Healthy men and women with overweight or obesity
1,000 mg/day · 6 weeks per phase
Fat-free mass was slightly higher after NR (change 1.34%) and sleeping metabolic rate rose. No effects were found on insulin sensitivity, mitochondrial function, liver fat, blood pressure or inflammation markers.
Row on the Nicotinamide riboside (NR) page · PubMed 32320006 (opens PubMed)
Grade CInsulin sensitivity and glucose metabolism · No difference
RCT · n 40 · 2018 · Sedentary men aged 40–70 with obesity (BMI > 30) and insulin resistance
1,000 mg twice daily (2,000 mg/day) · 12 weeks
NR did not improve insulin sensitivity, glucose production, glucose disposal, energy expenditure, fat oxidation or body composition. No serious adverse events were observed.
Row on the Nicotinamide riboside (NR) page · PubMed 29992272 (opens PubMed)